SCHEMBL4773757

SCHEMBL4773757

NCCCc1ncccc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.48
CXCR4 P61073 3/20 0.46
HRH1 P35367 6/20 0.43
PDPK1 O15530 2/20 0.40
CHRNA7 P36544 1/20 0.38
HSP90AA1 P07900 2/20 0.37
HSP90AB1 P08238 2/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
BLM P54132 1/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
IDO1 P14902 1/20 0.35
PSMB5 P28074 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.34
APAF1 O14727 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8348255 0.94 HRH1 (0.50) CYP2A6CXCR4HRH1PDPK1CHRNA7
SCHEMBL8348237 0.92 HRH1 (0.53) CYP2A6CXCR4HRH1PDPK1
SCHEMBL8346110 0.88 HRH1 (0.47) CYP2A6CXCR4HRH1CHRNA7HSP90AA1
SCHEMBL510211 0.82 CYP2C9 (0.43) CXCR4PDPK1L3MBTL1
Hydrochloric Acid SCHEMBL28992846 0.81 CYP2C9 (0.42) CXCR4PDPK1MEN1MAPTKMT2A
SCHEMBL5369216 0.81 TDP1 (0.49) CXCR4PDPK1MEN1MAPTKMT2A
SCHEMBL26931374 0.80 CYP2A6 (0.48) CYP2A6CXCR4HRH1CHRNA7ALDH1A1
SCHEMBL5746124 0.79 TDP1 (0.47) CXCR4PDPK1MEN1MAPTKMT2A
SCHEMBL5745538 0.79 TDP1 (0.47) CXCR4PDPK1MEN1MAPTKMT2A
SCHEMBL5748952 0.79 TDP1 (0.47) CXCR4PDPK1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322309-B1 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2008-08-13 EP disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
US-20070027158-A1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION 2007-02-01 US disclosed
US-6884815-B1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2005-04-26 US disclosed
EP-1322309-A4 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2004-10-13 EP disclosed
US-6723743-B1 TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS NEUROGEN CORPORATION 2004-04-20 US disclosed
EP-1322309-A2 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2003-07-02 EP disclosed
WO-2002049993-A2 HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2002-06-27 WO disclosed
WO-1999021870-A1 ERYTHROMYCIN A 11, 12-CARBAMATE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027158-A1 High affinity small molecule C5a receptor modulators C3AR1, C5AR1, C5AR2 CYP2A6 1018/4885CXCR4 154/4885HRH1 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.